Nanobiotix FY2026 EPS Forecast Increased by HC Wainwright

Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) – Research analysts at HC Wainwright raised their FY2026 earnings per share estimates for shares of Nanobiotix in a research report issued on Monday, April 13th. HC Wainwright analyst S. Ramakanth now expects that the company will earn $1.41 per share for the year, up from their previous estimate of $1.05. The consensus estimate for Nanobiotix’s current full-year earnings is ($1.18) per share. HC Wainwright also issued estimates for Nanobiotix’s FY2027 earnings at ($0.05) EPS, FY2028 earnings at $0.83 EPS, FY2029 earnings at $1.51 EPS and FY2030 earnings at $2.65 EPS.

Nanobiotix (NASDAQ:NBTX) last issued its earnings results on Sunday, February 15th. The company reported ($0.23) EPS for the quarter. The business had revenue of $3.42 million for the quarter.

Several other brokerages have also recently commented on NBTX. Weiss Ratings reiterated a “sell (d-)” rating on shares of Nanobiotix in a research report on Thursday, January 22nd. TD Cowen reiterated a “buy” rating on shares of Nanobiotix in a research report on Thursday, March 12th. Finally, Guggenheim upped their target price on shares of Nanobiotix from $26.00 to $36.00 and gave the company a “buy” rating in a research report on Thursday, April 2nd. Four analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, Nanobiotix currently has a consensus rating of “Moderate Buy” and an average price target of $25.00.

Nanobiotix Trading Up 4.3%

Shares of Nanobiotix stock opened at $33.20 on Wednesday. The firm has a fifty day moving average of $29.86 and a two-hundred day moving average of $24.50. Nanobiotix has a 52 week low of $3.12 and a 52 week high of $41.89.

Institutional Trading of Nanobiotix

A number of large investors have recently made changes to their positions in the company. Royal Bank of Canada increased its position in shares of Nanobiotix by 2,000.0% in the 4th quarter. Royal Bank of Canada now owns 2,625 shares of the company’s stock valued at $61,000 after buying an additional 2,500 shares in the last quarter. Optiver Holding B.V. bought a new stake in shares of Nanobiotix in the 3rd quarter valued at $101,000. Marshall Wace LLP bought a new stake in shares of Nanobiotix in the 4th quarter valued at $220,000. Finally, Millennium Management LLC bought a new stake in shares of Nanobiotix in the 4th quarter valued at $390,000. Institutional investors own 38.81% of the company’s stock.

Nanobiotix Company Profile

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.